Uterine Cancer Progression
Uterine Cancer Progression - Related Videos
09:25
Bioluminescent Orthotopic Model of Pancreatic Cancer Progression
0 Views •
Cited by 34 •
2013
Improved understanding of pancreatic cancer biology is critically needed to enable the development of better therapeutic options to treat pancreatic cancer. To address this need, we demonstrate an orthotopic model of pancreatic cancer that permits non-invasive monitoring of cancer progression using in vivo bioluminescence imaging.
04:20
Intra-uterine Cancer Cell Injection: A Technique to Deliver Cancer Cells for Establishing Intra-peritoneal Ovarian Cancer Mouse Model
0 Views •
2023
In this video, we demonstrate intra-uterine injection of ovarian cancer cells in a mouse model. This orthotopic murine model helps us to non-invasively monitor tumor growth and evaluate the efficacy of new therapies for the prevention and treatment of recurrent ovarian cancer.
03:19
Generating PDOX Mouse Model of Colorectal Cancer: Studying Progression of Colorectal Cancer in a Murine Model
0 Views •
2023
This video describes the protocol for generating a patient-derived orthotopic xenograft colorectal cancer mouse model to study the progression of colorectal cancer cells in non-obese diabetic/severe combined immunodeficiency (NOD/SCID) mice. This murine model helps in understanding primary tumor growth and metastases pattern.
03:03
mTOR Signaling and Cancer Progression
0 Views •
2023
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors. The mTOR pathway or the...
03:03
mTOR Signaling and Cancer Progression
0 Views •
2021
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors. The mTOR pathway or the...
FAQs
Molecular alterations can change several cellular behaviors at once. They may promote uncontrolled proliferation, help abnormal cells resist cell death, and support remodeling of surrounding tissue. Together, these changes allow tumor populations to persist and expand rather than being eliminated by normal controls. In cancer research, linking particular alterations to these behaviors helps explain why disease becomes more aggressive.
The tumor microenvironment can influence whether abnormal uterine cells survive and invade. Interactions between tumor cells and surrounding tissue may provide conditions that support invasion and continued survival, rather than treating the tumor as an isolated mass. Examining this relationship broadens progression research beyond tumor-cell genetics and can reveal why local surroundings matter when assessing potential spread or therapeutic targets.
Local invasion and distant spread represent different progression-related outcomes. Invasion refers to tumor cells moving into nearby tissues, whereas metastatic spread occurs when cells enter lymphatic or blood vessels and potentially reach distant organs. Distinguishing these patterns helps researchers and clinicians characterize how far disease has advanced, supporting staging decisions and attention to therapies aimed at limiting metastatic spread.
Researchers use changes in tumor behavior and biology to inform stage, prognosis, and biomarker discovery. Evidence of tissue invasion, vessel entry, survival advantages, or altered growth can provide information beyond the presence of abnormal cells alone. These measurements help estimate likely disease course and identify biological markers that may be useful for classification, treatment planning, or evaluating progression.
A progression study can compare abnormal cells with surrounding tissue and evaluate proliferation, resistance to cell death, tissue remodeling, invasion, vessel entry, and interactions with the microenvironment. Researchers can then relate these observations to biomarkers, disease stage, and prognosis. This integrated approach connects cellular mechanisms with clinically meaningful outcomes without reducing progression to a single molecular change.
Findings about progression guide both diagnosis and treatment planning. Researchers can use progression-associated changes to define disease stage, estimate prognosis, and search for biomarkers. Therapeutic development may then focus on tumor growth, survival, invasion, or metastatic spread. The value of this approach lies in connecting mechanistic evidence with decisions about how aggressively disease should be characterized and treated.